This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Aug 6;378(9790):459-60.

doi: 10.1016/S0140-6736(11)60980-X. Epub 2011 Jun 28.

Anti-CD3 antibodies for type 1 diabetes: beyond expectations

Jean-François Bach¹

Affiliations

PMID: 21719098
DOI: 10.1016/S0140-6736(11)60980-X

Comment

Anti-CD3 antibodies for type 1 diabetes: beyond expectations

Jean-François Bach. Lancet. 2011.

. 2011 Aug 6;378(9790):459-60.

doi: 10.1016/S0140-6736(11)60980-X. Epub 2011 Jun 28.

Author

Jean-François Bach¹

Affiliation

¹ Université Paris Descartes, Paris, France. jean-francois.bach@academie-sciences.fr

PMID: 21719098
DOI: 10.1016/S0140-6736(11)60980-X

No abstract available

PubMed Disclaimer

Comment on

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators. Sherry N, et al. Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28. Lancet. 2011. PMID: 21719095 Free PMC article. Clinical Trial.

Similar articles

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr, Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators. Sherry N, et al. Lancet. 2011 Aug 6;378(9790):487-97. doi: 10.1016/S0140-6736(11)60931-8. Epub 2011 Jun 28. Lancet. 2011. PMID: 21719095 Free PMC article. Clinical Trial.
[One step towards restoration of self-tolerance in human autoimmune diseases].
Chatenoud L. Chatenoud L. Med Sci (Paris). 2007 Feb;23(2):167-71. doi: 10.1051/medsci/2007232167. Med Sci (Paris). 2007. PMID: 17291426 Review. French.
The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic.
Chatenoud L. Chatenoud L. Handb Exp Pharmacol. 2008;(181):221-36. doi: 10.1007/978-3-540-73259-4_10. Handb Exp Pharmacol. 2008. PMID: 18071948 Review.
A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. Herold KC, et al. Diabetes. 2005 Jun;54(6):1763-9. doi: 10.2337/diabetes.54.6.1763. Diabetes. 2005. PMID: 15919798 Free PMC article. Clinical Trial.
[Anti-CD3 monoclonal antibodies: a new step towards therapy in new-onset type 1 diabetes].
Chatenoud L. Chatenoud L. Med Sci (Paris). 2006 Jan;22(1):5-6. doi: 10.1051/medsci/20062215. Med Sci (Paris). 2006. PMID: 16386207 French. No abstract available.

See all similar articles

Cited by

Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial.
Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Zhou H, Yin Z, Chen Y, Zhang Y, Wang S, Shen J, Thaker H, Jain S, Li Y, Diao Y, Chen Y, Sun X, Fisk MB, Li H. Zhao Y, et al. BMC Med. 2013 Jul 9;11:160. doi: 10.1186/1741-7015-11-160. BMC Med. 2013. PMID: 23837842 Free PMC article. Clinical Trial.
Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice.
Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, Galleri L, Spagnuolo I, Steidler L, Van Huynegem K, Demetter P, Wasserfall C, Atkinson MA, Dotta F, Rottiers P, Gysemans C, Mathieu C. Takiishi T, et al. J Clin Invest. 2012 May;122(5):1717-25. doi: 10.1172/JCI60530. Epub 2012 Apr 9. J Clin Invest. 2012. PMID: 22484814 Free PMC article.
Platelet-Derived Mitochondria Display Embryonic Stem Cell Markers and Improve Pancreatic Islet β-cell Function in Humans.
Zhao Y, Jiang Z, Delgado E, Li H, Zhou H, Hu W, Perez-Basterrechea M, Janostakova A, Tan Q, Wang J, Mao M, Yin Z, Zhang Y, Li Y, Li Q, Zhou J, Li Y, Martinez Revuelta E, Maria García-Gala J, Wang H, Perez-Lopez S, Alvarez-Viejo M, Menendez E, Moss T, Guindi E, Otero J. Zhao Y, et al. Stem Cells Transl Med. 2017 Aug;6(8):1684-1697. doi: 10.1002/sctm.17-0078. Epub 2017 Jul 7. Stem Cells Transl Med. 2017. PMID: 28685960 Free PMC article. Clinical Trial.
Remission of autoimmune diabetes by anti-TCR combination therapies with anti-IL-17A or/and anti-IL-6 in the IDDM rat model of type 1 diabetes.
Jörns A, Ishikawa D, Teraoku H, Yoshimoto T, Wedekind D, Lenzen S. Jörns A, et al. BMC Med. 2020 Feb 28;18(1):33. doi: 10.1186/s12916-020-1503-6. BMC Med. 2020. PMID: 32106855 Free PMC article.
Anti-TCR therapy combined with fingolimod for reversal of diabetic hyperglycemia by β cell regeneration in the LEW.1AR1-iddm rat model of type 1 diabetes.
Jörns A, Akin M, Arndt T, Terbish T, Zu Vilsendorf AM, Wedekind D, Hedrich HJ, Lenzen S. Jörns A, et al. J Mol Med (Berl). 2014 Jul;92(7):743-55. doi: 10.1007/s00109-014-1137-2. Epub 2014 Mar 7. J Mol Med (Berl). 2014. PMID: 24599515

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information